Clinical Trial Update: Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer

View source ↗

Summary

This clinical trial update discusses using thymidine kinase 1 as a biomarker for risk assessment in hereditary breast and ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Breast Cancer, Ovarian Cancer | Status: UNKNOWN